Rockefeller Capital Management L.P. Purchases 25,415 Shares of Kymera Therapeutics, Inc. $KYMR

Rockefeller Capital Management L.P. increased its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 21,538.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 25,533 shares of the company’s stock after purchasing an additional 25,415 shares during the period. Rockefeller Capital Management L.P.’s holdings in Kymera Therapeutics were worth $1,987,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Kymera Therapeutics during the fourth quarter valued at approximately $198,000. Virtu Financial LLC bought a new stake in Kymera Therapeutics during the 4th quarter valued at $2,123,000. T. Rowe Price Investment Management Inc. raised its holdings in Kymera Therapeutics by 3.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 629,745 shares of the company’s stock worth $49,001,000 after buying an additional 18,524 shares during the last quarter. Invesco Ltd. raised its holdings in Kymera Therapeutics by 46.3% during the fourth quarter. Invesco Ltd. now owns 116,747 shares of the company’s stock worth $9,084,000 after buying an additional 36,940 shares during the last quarter. Finally, Vident Advisory LLC raised its holdings in shares of Kymera Therapeutics by 6.5% in the 4th quarter. Vident Advisory LLC now owns 7,581 shares of the company’s stock worth $590,000 after acquiring an additional 465 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Truist Financial lifted their price objective on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Morgan Stanley restated an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a report on Thursday, April 30th. Citigroup upped their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, B. Riley Financial increased their price objective on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $120.82.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $81.18, for a total value of $2,435,400.00. Following the completion of the sale, the chief executive officer directly owned 666,195 shares of the company’s stock, valued at $54,081,710.10. This trade represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the completion of the sale, the director owned 240,123 shares in the company, valued at approximately $25,573,099.50. The trade was a 86.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 2,935,983 shares of company stock valued at $310,618,303. Company insiders own 15.98% of the company’s stock.

Kymera Therapeutics Stock Up 1.1%

Kymera Therapeutics stock opened at $109.32 on Tuesday. Kymera Therapeutics, Inc. has a twelve month low of $36.65 and a twelve month high of $130.05. The firm has a 50 day moving average price of $85.27 and a 200-day moving average price of $82.38. The company has a market capitalization of $8.99 billion, a P/E ratio of -30.62 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The company had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. During the same quarter in the previous year, the firm posted ($0.82) EPS. Kymera Therapeutics’s revenue was up 55.5% on a year-over-year basis. Equities analysts expect that Kymera Therapeutics, Inc. will post -3.28 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.